Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Wrexham have taken a significant step toward boosting their stadium’s capacity, having officially submitted a planning application to Wrexham City Borough Council. The club aims to add an extra 2,250 ...

The market expects Stoke Therapeutics, Inc. (STOK) to deliver a year-over-year decline in earnings on higher revenues when it ...

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

The legal confrontation is not unprecedented, as Danone has previously sued Chobani at least twice in the past decade over ...

Wrexham ’s Racecourse Ground will have a new name next season for the second time in its history following a lucrative sponsorship deal that is expected to earn the club a substantial seven ...

STOK has a tiny market cap of $629.50 million and a rather large “short interest” of more than 21%. Last quarter the company saw a nice beat on both earnings ($1.90) and revenues ($158 million ...

Here are some of the largest recent moves: FMR LLC added 2,376,741 shares (+1438.7%) to their portfolio in Q1 2025, for an estimated $15,805,327 MARSHALL WACE, LLP added 1,180,351 shares (+124.1% ...